Naringin attenuates granule cell dispersion in the dentate gyrus in a mouse model of temporal lobe epilepsy

Epilepsy Res. 2016 Jul:123:6-10. doi: 10.1016/j.eplepsyres.2016.03.001. Epub 2016 Mar 14.

Abstract

Morphological abnormalities of the dentate gyrus (DG) are an important phenotype in the hippocampus of patients with temporal lobe epilepsy. We recently reported that naringin, a bioflavonoid in grapefruit and citrus fruits, exerts beneficial effects in the kainic acid (KA) mouse model of epilepsy. We found that naringin treatment reduced seizure activities and decreased autophagic stress and neuroinflammation in the hippocampus following in vivo lesion with KA. However, it remains unclear whether naringin may also attenuate seizure-induced morphological changes in the DG, collectively known as granule cell dispersion (GCD). To clarify whether naringin treatment reduces GCD, we evaluated the effects of intraperitoneal injection of naringin on GCD and activation of mammalian target of rapamycin complex 1 (mTORC1), an important regulator of GCD, following intrahippocampal injection of KA. Our results showed that naringin treatment significantly reduced KA-induced GCD and mTORC1 activation, which was confirmed by assessing the phosphorylated form of the mTORC1 substrate, 4E-BP1, in the hippocampus. These results suggest that naringin treatment may help prevent epilepsy-induced hippocampal injury by inhibiting mTORC1 activation and thereby reducing GCD in the hippocampus in vivo.

Keywords: Dentate gyrus; Granule cell dispersion; Kainic acid; Mammalian target of rapamycin complex 1; Naringin.

MeSH terms

  • Adaptor Proteins, Signal Transducing
  • Analysis of Variance
  • Animals
  • Carrier Proteins / metabolism
  • Cell Cycle Proteins
  • Dentate Gyrus / drug effects*
  • Dentate Gyrus / pathology
  • Disease Models, Animal
  • Epilepsy, Temporal Lobe / drug therapy*
  • Epilepsy, Temporal Lobe / metabolism
  • Epilepsy, Temporal Lobe / pathology
  • Eukaryotic Initiation Factors
  • Flavanones / pharmacology*
  • Flavanones / therapeutic use
  • Flavonoids / pharmacology*
  • Flavonoids / therapeutic use
  • Humans
  • Injections, Intraperitoneal
  • Kainic Acid / pharmacology
  • Male
  • Mechanistic Target of Rapamycin Complex 1 / antagonists & inhibitors*
  • Mice
  • Mice, Inbred C57BL
  • Neurons / drug effects
  • Neurons / metabolism
  • Phosphoproteins / metabolism

Substances

  • Adaptor Proteins, Signal Transducing
  • Carrier Proteins
  • Cell Cycle Proteins
  • Eif4ebp1 protein, mouse
  • Eukaryotic Initiation Factors
  • Flavanones
  • Flavonoids
  • Phosphoproteins
  • Mechanistic Target of Rapamycin Complex 1
  • naringin
  • Kainic Acid